Why is the European Unifying Recommendation for Treating Syndrome of Inappropriate Antidiuretic Hormone (SIADH) and Cerebral Renal Salt Wasting Not Commonly Recommended in the US

为什么欧洲统一推荐的抗利尿激素分泌异常综合征(SIADH)和脑肾失盐综合征治疗方案在美国不被普遍推荐?

阅读:1

Abstract

Hyponatremia in patients with the syndrome of inappropriate antidiuretic hormone (SIADH) and in patients with cerebral renal salt wasting (CRSW) requires radically different treatment. Delay in proper treatment often occurs because the laboratory presentation of both syndromes is identical, and the fact that CRSW is considered very rare. The parameters observed are hyponatremia, hypouricemia with high fractional excretion of uric acid, normal renal, adrenal and thyroid function, concentrated urine with urine osmolality higher than plasma osmolality, and urine sodium concentration often > 30 mmol/L. The treatment of SIADH requires fluid restriction or forced fluid excretion, while the treatment of CRSW requires fluid administration. Delays in treatment may result in serious, possibly fatal complications. A unifying treatment protocol has been developed in Europe but is often ignored in the American literature. The European approach introduces a safer treatment of severe hyponatremia when the physician is confronted with either SIADH or CRSW. It recommends initial treatment with boluses of 3% saline over 20 minutes via a peripheral vein, with modifications of the treatment to increase serum sodium by 5 mEq. over the next 1-2 hours.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。